No virological failure in semen during properly suppressive antiretroviral therapy despite subtherapeutic local drug concentrations

HIV Clinical Trials

Volumn 7, Issue 6, 2006, Pages 285-290

  Lowe, Selwyn H ^a,b   Wensing, Annemarie M J ^c,d   Droste, Jacqueline A H ^e   ten Kate, Reinier W ^f   Jurriaans, Suzanne ^a   Burger, David M ^e   Borleffs, Jan C C ^d   Lange, Joep M A ^a,b   Prins, Jan M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b International Antiviral Therapy Evaluation Center   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f Infection and Immunology   (Netherlands)

Author keywords

Antiviral drug concentration; HIV 1 RNA concentration; Seminal plasma; Source of HIV

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; MESSENGER RNA; NELFINAVIR; RITONAVIR; SAQUINAVIR; STAVUDINE;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG TISSUE LEVEL; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SEMINAL PLASMA; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS INHIBITION;

EID: 33846490258     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct0706-285     Document Type: Article

References (22)

1. Lowe SH, Sankatsing SU, Repping S, et al. Is the male genital tract really a sanctuary site for HIV? Arguments that it is not. AIDS. 2004;18:1353-1362.
2. Taylor S, Boffito M, Vernazza PL. Antiretroviral therapy to reduce the sexual transmission of HIV. J HIV Ther. 2003; 8:55-66.
3. Lowe SH, Wensing AMJ, Hassink EAM, et al. Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES). HIV Clin Trials. 2005;6:235-245.
4. Barroso PF, Schechter M, Gupta P, et al. Effect of antiretroviral therapy on HIV shedding in semen. Ann Intern Med. 2000;133:280-284.
5. Liuzzi G, Chirianni A, Bagnarelli P, Clementi M, Piazza M. A combination of nucleoside analogues and a protease inhibitor reduces HIV-1 RNA levels in semen: implications for sexual transmission of HIV infection. Antivir Ther. 1999;4: 95-99.
6. Eron JJ, Vernazza PL, Johnston DM, et al. Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: implications for transmission. AIDS. 1998;12:F181-F189.
7. Kroodsma KL, Kozal MJ, Hamed KA, Winters MA, Merigan TC. Detection of drug resistance mutations in the human immunodeficiency virus type 1 (HIV-1) pol gene: differences in semen and blood HIV-1 RNA and proviral DNA. J Infect Dis. 1994;170:1292-1295.
8. Notermans DW, de Wolf F, Oudshoorn P, et al. Evaluation of a second-generation Nucleic Acid Sequence-Based Amplification Assay for quantification of HIV type 1 RNA and the use of ultrasensitive protocol adaptations. AIDS Res Hum Retroviruses. 2000;16:1507-1517.
9. Back D, Blaschke T, Boucher C, et al. Therapeutic drug monitoring guidelines: therapeutic ranges for antiretroviral drugs. 2003. Available at: www.HIVPharmacology.com.
10. Droste JA, Verweij-Van Wissen CP, Burger DM. Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography. Ther Drug Monit. 2003;25:393-399.
11. Aarnoutse RE, Grintjes KJ, Telgt DS, et al. The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers. Clin Pharmacol Ther. 2002;71:57-67.
12. Taylor S, Back DJ, Drake SM, et al. Antiretroviral drug concentrations in semen of HIV-infected men: differential penetration of indinavir, ritonavir and saquinavir. J Antimicrob Chemother. 2001;48:351-354.
13. Taylor S, Back DJ, Workman J, et al. Poor penetration of the male genital tract by HIV-1 protease inhibitors. AIDS. 1999;13:859-860.
14. Solas C, Lafeuillade A, Halfon P, Chadapaud S, Hittinger G, Lacarelle B. Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2003;47:238-243.
15. Schuurman R, Nijhuis M, van Leeuwen R, et al. Rapid changes in human immunodeficiency virus type I RNA load and appearance of drug resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis. 1995;171:1411-1419.
16. Foudraine NA, de Jong JJ, Jan WG, et al. An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine. AIDS. 1998;12:1513-1519.
17. Gisslen M, Hagberg L. Antiretroviral treatment of central nervous system HIV-1 infection: a review. HIV Med. 2001;2:97-104.
18. Dejucq N, Jegou B. Viruses in the mammalian male genital tract and their effects on the reproductive system. Microbiol Mol Biol Rev. 2001;65:208-231.
19. Zhang H, Dornadula G, Beumont M, et al. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretoviral therapy. N Engl J Med. 1998;339:1803-1809.
20. Dornadula G, Zhang H, VanUitert B, et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA. 1999;282:1627-1632.
21. Xu C, Politch JA, Mayer KH, Anderson DJ. Human immunodeficiency virus type-1 episomal cDNA in semen. AIDS Res Ther. 2005;2:9.
22. Vernazza PL. HIV in semen: still more to be learned. AIDS Res Ther. 2005;2:11.